Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBI-001 and DBI-002 in Onychomycosis
NCT05491603Phase 2Suspended
- Sponsor
- DermBiont, Inc.
- Start
- Nov 2023
- Primary completion
- Nov 2023
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of DBI-001 and DBI-002 probiotic gel in onychomycosis (3 arms), sponsored by DermBiont, Inc. Primary endpoints: Change in percentage of involved great toenail(s) at 24 weeks and Changes in signs and symptoms of Onychomycosis at 48 weeks. Started Nov 2023; status: suspended.
02
Drugs
DBI-001DBI-002 probiotic gel
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT05491603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491603.